

NEW ZEALAND DATA SHEET

1 PRODUCT NAME (strength pharmaceutical form)

CHLORHEXIDINE ACETATE 0.05% (0.05%, solution, antiseptic).

CHLORHEXIDINE ACETATE 0.1% (0.1%, solution, antiseptic).

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active Ingredients

Chlorhexidine acetate BP 0.05% w/v and 0.1% w/v.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Solution, antiseptic.

Physical characteristics

CHLORHEXIDINE ACETATE 0.05% and **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions are clear, slightly blue sterile solutions.

The solution is hypotonic and is haemolytic.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

CHLORHEXIDINE ACETATE 0.05% and **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions are used as a general antiseptic. They are used for the cleaning and disinfecting of wounds and the antiseptic treatment of burns.

4.2 Dose and method of administration

Dosage

As required to disinfect wound area. See Directions for use. Dosage and duration of administration are to be individualized and depend upon the indication for use, the patient's ages, weight, clinical condition, concomitant treatment and on patient's clinical response to treatment (see section 4.4).

Not for intravenous or oral route of administration.

Product should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit. Do not use unless the solution is clear and the seal is intact.

Directions for use

The area where **CHLORHEXIDINE ACETATE 0.05%** and/or **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions are to be used should be rinsed thoroughly with water. Apply the minimum amount necessary to cover the wound area and wash gently. Allow to dry for 3 minutes.

Discard within 24 hours of opening.

This solution is used as a general antiseptic, and is also recommended for disinfection of respirators.

NEW ZEALAND DATA SHEET

To open

Hold Steripour® bottle and twist lid to open, breaking the tamper proof seal.

4.3 Contraindications

Known hypersensitivity to chlorhexidine acetate or methylene blue or to any of the excipients listed in section 6.1.

CHLORHEXIDINE ACETATE 0.05% and **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions should not be used in the eye, intravenously, orally, in the auditory canal (especially perforated eardrums) or near meninges, brain or spinal cord.

4.4 Special warnings and precautions for use

General

- **CHLORHEXIDINE ACETATE 0.05%** and **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions should not be used intravenously or taken orally. Do not swallow. If swallowed seek urgent medical attention.
- It should not be used if you have a history of allergy to any of the ingredients of **CHLORHEXIDINE ACETATE 0.05%** and/or **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions.
- The use of chlorhexidine as a mouthwash has been associated with reversible discolouration of the tongue, teeth, and silicate or composite dental restorations.
- It should not be used if the expiry date printed on the label is overdue. Do not use unless the solution is clear, free of particles and the tamper proof seal is intact.

Hypersensitivity Reactions

- Hypersensitivity reactions including anaphylactic/anaphylactoid reactions have been reported with chlorhexidine acetate. Fatal anaphylactic reactions have been reported with other products containing chlorhexidine acetate.
- If any signs or symptoms of a suspected hypersensitivity reaction develop, immediately stop using the product. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

Chemical Burns in Neonates

- The use of chlorhexidine acetate solutions, both alcohol based and aqueous, for skin antisepsis prior to invasive procedures has been associated with skin reactions such as chemical burns in neonates. Based on available case reports in the published literature, this risk appears to be higher in preterm infants, especially those born before 32 weeks of gestation and within the first 2 weeks of life.
- Remove any soaked materials, drapes or gowns before proceeding with the intervention. Do not use excessive quantities and do not allow the solution to pool in skin folds or under the patient or drip on sheets or other material in direct contact with the patient. Where occlusive dressings are to be applied to areas previously exposed to **CHLORHEXIDINE ACETATE 0.05%** and/or **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions, care must be taken to ensure no excess product is present prior to application of the dressing.

NEW ZEALAND DATA SHEET

Preoperative Skin preparation

CHLORHEXIDINE ACETATE 0.05% and **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions should not be used in preoperative skin preparations for face or head.

Paediatric Use

This product is safe for use on children.

The use of chlorhexidine solutions has been associated with skin reactions such as chemical burns in neonates.

4.5 Interaction with other medicines and other forms of interaction

The action of chlorhexidine acetate is reduced by an alkaline pH, the presence of organic matter, anionic detergents and tannins.

4.6 Fertility, pregnancy and lactation

Fertility

The effects of chlorhexidine acetate on human reproduction have not been studied.

Pregnancy (Category A)

The "Prescribing Medicines in Pregnancy" booklet categorises chlorhexidine as a Category A medicine.

Breast-feeding

This product is safe for use in lactation.

4.7 Effects on ability to drive and use machines

CHLORHEXIDINE ACETATE 0.05% and **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions have no influence on the ability to drive and use machines.

4.8 Undesirable effects

Anaphylactic/anaphylactoid reactions to chlorhexidine acetate have been reported. Manifestations of such reactions have included cardiac arrest, circulatory collapse, hypotension, bronchospasm, rash, erythema, tachycardia, urticaria and shock. Fatal anaphylactic reaction has been reported.

Some patients may experience skin irritation or an allergic reaction/ hypersensitivity reactions on contact with this product. If this occurs, the use of this product should be stopped immediately. Skin sensitivity to chlorhexidine acetate has occasionally been reported.

Very occasionally the following reactions have been noted when chlorhexidine acetate containing irrigating solutions have been used intravesically, intravaginally or topically on traumatised skin: hypotension, paraesthesia, dyspnoea, tachycardia cold sweat, generalized erythema, urticaria and loss of consciousness.

Strong solutions may cause irritation of the conjunctiva and other sensitive tissues. Transient taste disturbances and burning sensation of the tongue may occur on initial use.

NEW ZEALAND DATA SHEET

Oral desquamation and occasional parotid gland swelling have been reported with the mouthwash. If desquamation occurs, a 50% dilution of the mouthwash with water and less vigorous rinsing may allow continued use.

Chemical burns in neonates have been reported with similar chlorhexidine solutions (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions
<https://nzphvc.otago.ac.nz/reporting/>

4.9 Overdose

Chlorhexidine acetate is poorly absorbed by the gastrointestinal tract. If ingested, advice concerning treatment should be sought immediately from a doctor.

For advice on the management of overdose please contact the National Poisons Centre on phone number: 0800 764 766 [0800 POISON] in New Zealand (or 131126 in Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Blood and Blood Forming Organs/Blood Substitutes and Perfusion Solutions/Irrigating Solutions/Anti-infectives/Chlorhexidine

ATC code: B05CA02.

Molecular formula: $C_{22}H_{30}Cl_2N_{10}O_2$

CAS Numbers: Chlorhexidine (CAS number: 55-56-1) and Acetate (CAS number: 56-95-1)

Chemical Name: 1,1-hexamethylenebis[4-(4-chlorophenyl)biguanide] diacetate.

5.2 Pharmacokinetic properties

CHLORHEXIDINE ACETATE 0.05% and CHLORHEXIDINE ACETATE 0.1% antiseptic solutions are used as topical solutions.

5.3 Preclinical safety data

Not applicable.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Inactive Ingredients:

CHLORHEXIDINE ACETATE 0.05% and CHLORHEXIDINE ACETATE 0.1% antiseptic solutions: methyl blue, glacial acetic acid and Water for Injections BP.

NEW ZEALAND DATA SHEET

6.2 Incompatibilities

Prolonged immersion of rubber appliances in these solutions should be avoided.
Chlorhexidine is incompatible with soaps, other anionic materials and with potassium iodide.

6.3 Shelf life

24 months.

6.4 Special precautions for storage

Please see following table for specific storage conditions.

Do not heat in excess of 80°C. Protect from light.

6.5 Nature and contents of container

CHLORHEXIDINE ACETATE 0.05% and CHLORHEXIDINE ACETATE 0.1% antiseptic solutions are supplied in the pack sizes listed in the following table. They are packaged in plastic pour bottles, sealed with tamper proof lids.

Strength	Pack size	Storage requirements	Product Code	TT50-
Chlorhexidine Acetate 0.05%	100mL	Store below 30°C	AHF7977	3229
Chlorhexidine Acetate 0.05%	500mL	Store below 30°C	AHF7983	3229
Chlorhexidine Acetate 0.05%	1000mL	Store below 30°C	AHF7984	3229
Chlorhexidine Acetate 0.1%	100mL	Store below 30°C	AHF7978	3229/2
Chlorhexidine Acetate 0.1%	500mL*	Store below 25°C	AHF7985	3229/2
Chlorhexidine Acetate 0.1%	1000mL*	Store below 25°C	AHF7986	3229/2

*Not marketed.

6.6 Special precautions for disposal

Any unused medicine or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE

General Sale Medicine.

8 SPONSOR

CHLORHEXIDINE ACETATE 0.05% and CHLORHEXIDINE ACETATE 0.1% antiseptic solutions are distributed in New Zealand by:

Baxter Healthcare Ltd
33 Vestey Drive
Mt Wellington
Auckland 1060.

Baxter Healthcare Ltd
PO Box 14 062
Panmure
Auckland 1741

Phone (09) 574 2400.

NEW ZEALAND DATA SHEET

CHLORHEXIDINE ACETATE 0.05% and **CHLORHEXIDINE ACETATE 0.1%** antiseptic solutions are distributed in Australia by:

Baxter Healthcare Pty Ltd
1 Baxter Drive
Old Toongabbie, NSW 2146.

9 DATE OF FIRST APPROVAL

Date of publication in the New Zealand Gazette of consent to distribute the medicine:

CHLORHEXIDINE ACETATE 0.05% antiseptic solution: 11 March 1982.

CHLORHEXIDINE ACETATE 0.1% antiseptic solution: 11 March 1982.

10 DATE OF REVISION OF THE TEXT

28 November 2019.

SUMMARY TABLE OF CHANGES

Section changed	Summary of new information
All	Data Sheet created for this product range.
All	Trade names changed to Chlorhexidine Acetate 0.05% and Chlorhexidine Acetate 0.1%

Based on Australian PI most recent amendment 13 September 2016.

Please refer to the Medsafe website (www.medsafe.govt.nz) for most recent data sheet.

Baxter is a trademark of Baxter International Inc. SteriPour is a registered trademark of Baxter International Inc.